Invasive Fungal Diseases in Children with Hematological Malignancies Treated with Therapies That Target Cell Surface Antigens: Monoclonal Antibodies, Immune Checkpoint Inhibitors and CAR T-Cell Therapies

Since 1985 when the first agent targeting antigens on the surface of lymphocytes was approved (muromonab-CD3), a multitude of such therapies have been used in children with hematologic malignancies. A detailed literature review until January 2021 was conducted regarding pediatric patient populations...

Descripción completa

Detalles Bibliográficos
Autores principales: Kyriakidis, Ioannis, Vasileiou, Eleni, Rossig, Claudia, Roilides, Emmanuel, Groll, Andreas H., Tragiannidis, Athanasios
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7999508/
https://www.ncbi.nlm.nih.gov/pubmed/33807678
http://dx.doi.org/10.3390/jof7030186

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7999508/
https://www.ncbi.nlm.nih.gov/pubmed/33807678
http://dx.doi.org/10.3390/jof7030186

Ejemplares similares